乔治临床( George Clinical ) welcomes the decision by the FDA to approve the delivery of CAR-T therapy in a partnership between Methodist Healthcare, and 乔治临床( George Clinical ) Scientific Leader, […]
了解更多Beijing, November 13, 2018 – 乔治临床( George Clinical ), a leading clinical research organization (CRO) in the Asia-Pacific region, has continued its involvement and collaboration with the Heart […]
了解更多9 AUGUST, 2018 – (BEIJING) In another positive development in China’s rapidly evolving regulatory environment The China National Drug Administration (CNDA) has introduced a 60-day window […]
了解更多
In another encouraging step towards making China a leading destination for clinical drug trials, some critical developments were announced at The Executive Meeting of the State Council on the […]
了解更多
George Clinical, a leading full-service CRO in the US and Asia-Pacific region, is pleased to announce that Matthew Reabold, Sr. has been promoted to the Head of Business Development, USA. 乔治临床 […]
了解更多
Significant changes are ahead for clinical research in China. The Public Consultation Notice for Policies to Encourage Innovation and Reform in Regulation of Drug and Medical Device Clinical T […]
了解更多
Sydney, Australia (May 2, 2017) – 乔治临床( George Clinical ), a leading full-service CRO in the Asia-Pacific region and Vector Oncology, a Memphis-based leader in oncology research and data analy […]
了解更多
乔治临床( George Clinical ) is pleased to announce the receipt of their Hong Kong Wholesale Dealer licence issued by the Department of Health on the 3rd April. This licence represents a significan […]
了解更多
Taiwan sits, along with its smaller counterparts, Singapore and Hong Kong, as one of the gateway countries to running a clinical trial in China. Although Hong Kong’s regulatory ties are more f […]
了解更多
Clinical trial sponsors and CROs don’t need to imagine South Korea as a country of limitless potential, they know it is. South Korea is a clinical trial destination with world-class medical in […]
了解更多
